strips, and among non-insulin-treated patients this was commoner among women, younger people and less deprived groups. Conclusions: The numbers of reagent strips dispensed for SMBG has increased, and almost all insulin-treated patients receive strips. While few diet-treated patients receive strips, they are more extensively dispensed to those treated with oral agents. Given that SMBG is no longer routinely recommended in non-insulin treated patients, strategies to reduce unnecessary dispensing of reagent strips are needed.
Introduction
Self-monitoring of blood glucose (SMBG) is considered an integral part of treatment for people with type 1 diabetes, and those with type 2 diabetes who use insulin 1, 2 .
These patients can use SMBG readings to adjust insulin doses themselves, if appropriate, thereby assisting optimal glycaemic control. However, the benefits of SMBG among people with type 2 diabetes who do not use insulin are much less certain. Recent trials, reviews and meta-analyses have shown either no or very small effects of SMBG on glycaemic control 3, 4, 5 . Given that there is also concern over the high costs associated with SMBG 6 and possible adverse psychological consequences 7, 8 , national guidelines state that routine monitoring is no longer recommended for patients who do not use insulin 9, 10 , although it may benefit certain groups (eg users of sulponlyureas to reduce risk of hypoglycaemia) 1 .
While the benefits of SMBG amongst non-insulin treated patients have been questioned, some (albeit limited) research suggests there has been a large increase in the numbers of patients who undertake SMBG. A UK survey in primary care found that over 80% of patients, including those treated with oral agents, did some monitoring, albeit this research involved a small self-selected patient group 11 .
Electronic prescribing records may provide a more objective picture of monitoring patterns, and a study using the General Practice Research Database (GPRD), indicated that prescriptions written for monitoring reagent strips among patients newly treated with oral agents increased from 19% to 32% between 1993 and 1998 12 . The most recent analysis used IMS-Mediplus data for 40,094 patients with type 2 diabetes from 670 GP practices in the UK, and concluded that, in 2007, the proportion of patients treated with oral agents who self-monitored ranged from 36% to 58%, depending on the particular (combinations of) oral agents 13 . However, perhaps more surprisingly, the same proportion for patients treated by diet/exercise only was found to be as high as 26%. . For every patient, we collated all prescriptions dispensed for blood reagent strips during the relevant calendar year. We were able to calculate the exact numbers of reagent strips dispensed for SMBG from details on the prescription. We recordlinked these data to clinical and demographic information. We then categorised patients into those who had also received any prescription for insulin during the year as insulin-treated, those who received prescriptions for oral agents only as oraltreated, and the remaining patients as diet-treated. For the 2009 sample, we were also able to identify patients in the oral-treated group who had received any prescription for sulphonylureas. We investigated whether monitoring patterns were associated with age, sex and a postcode measure of social and material deprivation (SIMD) that classified people into quintiles of deprivation. This incorporates information on income, employment, health and disability, education, skills and training, and access to services, for small geographical areas 16 . To explore factors associated with whether or not a patient was dispensed reagent strips for any SMBG, we used logistic regression analysis to obtain adjusted odds ratios (with 95% confidence intervals) for proportion is now over 90%. Among patients who received any reagent strips, the total numbers of strips dispensed also increased among patients treated with oral agents and insulin over the study period. The mean number of strips dispensed among insulin-treated patients is sufficient for daily monitoring. For those treated with oral agents, sufficient strips are dispensed for monitoring 3-4 times weekly. The proportion monitoring and the mean number of strips dispensed were higher among patients who were treated with sulphonylureas. However, there was still one fifth of patients treated with metformin and other oral agents who were receiving reagent strips for SMBG. Table 2 shows that receiving reagent strips for SMBG among patients not treated with insulin is more common among women and less deprived groups, but decreases with increasing age, with the odds ratios indicating independent effects of each of these factors. The associations are particularly evident for patients treated with oral agents.
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Discussion
This study has confirmed a general increase in reagent strips dispensed for SMBG among all patients with type 2 diabetes over the past 15 years. While it is encouraging that over 90% of insulin-treated patients receive reagent strips, and obtain sufficient numbers to monitor daily, the increase in non insulin treated patients receiving reagent strips may be cause for concern, particularly among patients treated with oral agents.
This study measured the number of reagent strips that were dispensed to patients in community pharmacies. Although we cannot be sure whether patients actually used all the strips that were dispensed to them, and they may also have received strips from other sources, the study has identified clear trends over time. We also consider that dispensed prescribing records for an entire diabetic population may provide a more objective measure of actual monitoring behaviour than self-report from selected samples of patients. Nevertheless the finding that only 5.6% of diet-treated patients received reagent strips for SMBG stands in stark contrast to the 26% reported using electronic IMS-Mediplus data from 670 GP practices 13 . That study used QoF data (Quality and Outcomes Framework) to locate patients with diabetes, hence it was able to identify only those who were receiving active treatment and monitoring. In contrast, the SCI-DC diabetes register in Tayside record-links information from several independent data sources and has high sensitivity and specificity for identifying all patients with diabetes 14 . Not only is the IMS-Mediplus study likely to have under-ascertained diet treated patients, patients who monitored were, by definition, more likely to have been identified. We therefore consider that our figure of 5.6% is a more realistic estimate of the prevalence of patients with type 2 diabetes who receive reagent strips for SMBG but who are not treated with oral agents or insulin.
The greatest increase in reagent strips dispensed for SMBG was observed in patients treated with oral agents, with 27.4% receiving strips in 2009. The mean number of strips per patient would enable monitoring 3-4 times per week. In some practices in Scotland, GPs are no longer writing prescriptions for reagent strips for such patients, and it may be that this figure has decreased slightly since 2009. However, although this figure is also lower than in the IMS-Mediplus study, probably for the reasons 9 already discussed, it is still substantial, given that routine monitoring is not recommended 1 . While the SIGN guidelines specify certain groups who may benefit from monitoring 1 , for example patients using sulphonylureas who are at high risk of hypoglycaemia, this is unlikely to apply to over one third of these patients.
In summary, given the recent introduction of guidelines recommending that people who are not treated with insulin do not routinely undertake SMBG, alongside increased rationing of monitoring strips, the challenge is to identify patients for whom carrying out monitoring is unlikely to be beneficial and to dissuade them from doing 
